Unlocking a New Paradigm in Cancer Therapeutics
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in over 17% of cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality and develops small molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit cancer cell growth and resistance.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2024
May 2023
Apr 2021
Sep 2019
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
